{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T02:48:25Z","timestamp":1789958905753,"version":"4.0.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,29]],"date-time":"2024-03-29T00:00:00Z","timestamp":1711670400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,29]],"date-time":"2024-03-29T00:00:00Z","timestamp":1711670400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflamm Regener"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>One should identify appropriate cell surface targets to develop new CAR-T cells. Currently, lineage-specific antigens such as CD19 or B cell maturation antigen (BCMA) are being used as targets for CAR-T cells. However, in most cancers, lineage-specific antigens cannot be used as targets because targeting normal counterparts expressing them causes fatal toxicity. Cancer-specific transcripts have been extensively searched for using transcriptome analysis, but only a few candidates were reported. We have been working on identifying tumor-specific antigen structures, for example constitutively activated conformer of integrin b7 in multiple myeloma. Recently, several researchers have been working on a logic gate system that can react only when two antigens are expressed on the cell surface.<\/jats:p>","DOI":"10.1186\/s41232-024-00329-2","type":"journal-article","created":{"date-parts":[[2024,3,29]],"date-time":"2024-03-29T04:48:22Z","timestamp":1711687702000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Identification of cancer-specific cell surface targets for CAR-T cell therapy"],"prefix":"10.1186","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9570-0947","authenticated-orcid":false,"given":"Naoki","family":"Hosen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,29]]},"reference":[{"key":"329_CR1","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/s41591-022-01726-1","volume":"28","author":"V Narayan","year":"2022","unstructured":"Narayan V, Barber-Rotenberg JS, Jung IY, Lacey SF, Rech AJ, Davis MM, et al. PSMA-targeting TGF\u03b2-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial. Nat Med. 2022;28:724\u201334.","journal-title":"Nat Med"},{"key":"329_CR2","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/mt.2010.24","volume":"18","author":"RA Morgan","year":"2010","unstructured":"Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 2010;18:843\u201351.","journal-title":"Mol Ther"},{"key":"329_CR3","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1038\/s41591-023-02363-y","volume":"29","author":"A Heczey","year":"2023","unstructured":"Heczey A, Xu X, Courtney AN, Tian G, Barragan GA, Guo L, et al. Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results. Nat Med. 2023;29:1379\u201388.","journal-title":"Nat Med"},{"key":"329_CR4","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1038\/s41586-022-04489-4","volume":"603","author":"RG Majzner","year":"2022","unstructured":"Majzner RG, Ramakrishna S, Yeom KW, Patel S, Chinnasamy H, Schultz LM, et al. GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature. 2022;603:934\u201341.","journal-title":"Nature"},{"key":"329_CR5","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1038\/s41591-022-01800-8","volume":"28","author":"C Qi","year":"2022","unstructured":"Qi C, Gong J, Li J, Liu D, Qin Y, Ge S, et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. Nat Med. 2022;28:1189\u201398.","journal-title":"Nat Med"},{"key":"329_CR6","doi-asserted-by":"publisher","first-page":"275ra22","DOI":"10.1126\/scitranslmed.aaa4963","volume":"7","author":"LA Johnson","year":"2015","unstructured":"Johnson LA, Scholler J, Ohkuri T, Kosaka A, Patel PR, McGettigan SE, et al. Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma. Sci Transl Med. 2015;7:275ra22.","journal-title":"Sci Transl Med"},{"issue":"399","key":"329_CR7","doi-asserted-by":"publisher","first-page":"eaaa0984","DOI":"10.1126\/scitranslmed.aaa0984","volume":"9","author":"DM O'Rourke","year":"2017","unstructured":"O\u2019Rourke DM, Nasrallah MP, Desai A, Melenhorst JJ, Mansfield K, Morrissette JJD, et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci Transl Med. 2017;9(399):eaaa0984.","journal-title":"Sci Transl Med"},{"key":"329_CR8","doi-asserted-by":"publisher","first-page":"257","DOI":"10.3389\/fimmu.2020.00257","volume":"11","author":"Y Akatsuka","year":"2020","unstructured":"Akatsuka Y. TCR-Like CAR-T cells targeting MHC-bound minor histocompatibility antigens. Front Immunol. 2020;11:257.","journal-title":"Front Immunol"},{"key":"329_CR9","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1016\/j.immuni.2016.05.014","volume":"44","author":"AD Posey Jr","year":"2016","unstructured":"Posey AD Jr, Schwab RD, Boesteanu AC, Steentoft C, Mandel U, Engels B, et al. Engineered CAR T cells targeting the cancer-associated Tn-glycoform of the membrane mucin MUC1 control adenocarcinoma. Immunity. 2016;44:1444\u201354.","journal-title":"Immunity"},{"key":"329_CR10","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1038\/nm.4431","volume":"23","author":"N Hosen","year":"2017","unstructured":"Hosen N, Matsunaga Y, Hasegawa K, Matsuno H, Nakamura Y, Makita M, et al. The activated conformation of integrin beta7 is a novel multiple myeloma-specific target for CAR T cell therapy. Nat Med. 2017;23:1436\u201343.","journal-title":"Nat Med"},{"key":"329_CR11","doi-asserted-by":"publisher","first-page":"eaax7706","DOI":"10.1126\/scitranslmed.aax7706","volume":"14","author":"K Hasegawa","year":"2022","unstructured":"Hasegawa K, Ikeda S, Yaga M, Watanabe K, Urakawa R, Iehara A, et al. Selective targeting of multiple myeloma cells with a monoclonal antibody recognizing the ubiquitous protein CD98 heavy chain. Sci Transl Med. 2022;14:eaax7706.","journal-title":"Sci Transl Med"},{"key":"329_CR12","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1016\/S0161-5890(97)00144-2","volume":"34","author":"IC Nicholson","year":"1997","unstructured":"Nicholson IC, Lenton KA, Little DJ, Decorso T, Lee FT, Scott AM, et al. Construction and characterisation of a functional CD19 specific single chain Fv fragment for immunotherapy of B lineage leukaemia and lymphoma. Mol Immunol. 1997;34:1157\u201365.","journal-title":"Mol Immunol"},{"key":"329_CR13","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13045-016-0256-3","volume":"9","author":"Y Nakazawa","year":"2016","unstructured":"Nakazawa Y, Matsuda K, Kurata T, Sueki A, Tanaka M, Sakashita K, et al. Anti-proliferative effects of T cells expressing a ligand-based chimeric antigen receptor against CD116 on CD34(+) cells of juvenile myelomonocytic leukemia. J Hematol Oncol. 2016;9:27.","journal-title":"J Hematol Oncol"},{"key":"329_CR14","doi-asserted-by":"publisher","first-page":"eaal3995","DOI":"10.1126\/sciimmunol.abl3995","volume":"7","author":"Q Xiao","year":"2022","unstructured":"Xiao Q, Zhang X, Tu L, Cao J, Hinrichs CS, Su X. Size-dependent activation of CAR-T cells. Sci Immunol. 2022;7:eaal3995.","journal-title":"Sci Immunol"},{"key":"329_CR15","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/s41586-023-05778-2","volume":"615","author":"AM Tousley","year":"2023","unstructured":"Tousley AM, Rotiroti MC, Labanieh L, Rysavy LW, Kim WJ, Lareau C, et al. Co-opting signalling molecules enables logic-gated control of CAR T cells. Nature. 2023;615:507\u201316.","journal-title":"Nature"},{"key":"329_CR16","doi-asserted-by":"publisher","first-page":"eabm0306","DOI":"10.1126\/scitranslmed.abm0306","volume":"14","author":"ML Sandberg","year":"2022","unstructured":"Sandberg ML, Wang X, Martin AD, Nampe DP, Gabrelow GB, Li CZ, et al. A carcinoembryonic antigen-specific cell therapy selectively targets tumor cells with HLA loss of heterozygosity in vitro and in vivo. Sci Transl Med. 2022;14:eabm0306.","journal-title":"Sci Transl Med"},{"issue":"591","key":"329_CR17","doi-asserted-by":"publisher","first-page":"eabe7378","DOI":"10.1126\/scitranslmed.abe7378","volume":"13","author":"JH Choe","year":"2021","unstructured":"Choe JH, Watchmaker PB, Simic MS, Gilbert RD, Li AW, Krasnow NA, et al. SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma. Sci Transl Med. 2021;13(591):eabe7378.","journal-title":"Sci Transl Med"}],"container-title":["Inflammation and Regeneration"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41232-024-00329-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41232-024-00329-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41232-024-00329-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,29]],"date-time":"2024-03-29T04:48:47Z","timestamp":1711687727000},"score":1,"resource":{"primary":{"URL":"https:\/\/inflammregen.biomedcentral.com\/articles\/10.1186\/s41232-024-00329-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,29]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["329"],"URL":"https:\/\/doi.org\/10.1186\/s41232-024-00329-2","relation":{},"ISSN":["1880-8190"],"issn-type":[{"value":"1880-8190","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,29]]},"assertion":[{"value":"18 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The author declares no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17"}}